Category Archives: News and Events

BriaCell Therapeutics Announces $5 Million Offering Priced At-the-Market Under Nasdaq Rules

Philadelphia & Vancouver, British Columbia – October 1, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...

BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor

Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with ...

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in ...

BriaCell Therapeutics Announces Closing of $8.5 Million Offering

Philadelphia & Vancouver, British Columbia – September 12, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...

BriaCell Therapeutics Announces $8.5 Million Offering Priced At-the-Market Under Nasdaq Rules

Philadelphia & Vancouver, British Columbia – September 11, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

• Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in ...

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer

• BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with ...

BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PHILADELPHIA, PA and VANCOUVER, British Columbia, September 9, 2024— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) ...

BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer

Progression free survival (PFS) extended to 9.1 months in ADC resistant patient – quadruple the ...

BriaCell Presents Clinical Efficacy Data at ASCO 2024

BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature Bria-IMT™ ...